Logo Image
|Articles|June 1, 2001

Pharmaceutical Executive

  • Pharmaceutical Executive-06-01-2001
  • Volume 0
  • Issue 0

Emotion - The New Brand Integrator

Author(s)Gil Bashe

Driven by the quest for innovation, the intensity of competition, and the pressure to create megabrands and megamergers, pharmaceutical executives are exploring an influential force still untapped by most marketing and communication departments-the power of emotion.

Articles in this issue

over 25 years ago

Industry Under Investigation

over 25 years ago

Emotion - The New Brand Integrator

over 25 years ago

For Love of the Game

over 25 years ago

Field of Dreams

over 25 years ago

Workshop: Access Options

over 25 years ago

Rx-to-OTC: Unwanted Attention

over 25 years ago

Emotion - Biotech Renaissance Man

over 25 years ago

Relocation: Coming to America

over 25 years ago

Stocks: Catching the Market Blues

over 25 years ago

Gathering Light

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Approves Tecentriq
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Read more
Naoki Okamura: Post-Patent Plan and Purpose
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
Read more